JP2014533938A - γインターフェロンを用いた抗原提示癌ワクチン - Google Patents

γインターフェロンを用いた抗原提示癌ワクチン Download PDF

Info

Publication number
JP2014533938A
JP2014533938A JP2014537355A JP2014537355A JP2014533938A JP 2014533938 A JP2014533938 A JP 2014533938A JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014533938 A JP2014533938 A JP 2014533938A
Authority
JP
Japan
Prior art keywords
melanoma
cells
cell
ifn
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014537355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533938A5 (cg-RX-API-DMAC7.html
Inventor
コーンフォース、アンドリュー
ディルマン、ロバート
Original Assignee
カリフォルニア ステム セル インコーポレイテッド
カリフォルニア ステム セル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア ステム セル インコーポレイテッド, カリフォルニア ステム セル インコーポレイテッド filed Critical カリフォルニア ステム セル インコーポレイテッド
Publication of JP2014533938A publication Critical patent/JP2014533938A/ja
Publication of JP2014533938A5 publication Critical patent/JP2014533938A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014537355A 2011-10-20 2012-10-22 γインターフェロンを用いた抗原提示癌ワクチン Pending JP2014533938A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2012/061294 WO2013059778A2 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Publications (2)

Publication Number Publication Date
JP2014533938A true JP2014533938A (ja) 2014-12-18
JP2014533938A5 JP2014533938A5 (cg-RX-API-DMAC7.html) 2016-02-25

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014537355A Pending JP2014533938A (ja) 2011-10-20 2012-10-22 γインターフェロンを用いた抗原提示癌ワクチン
JP2014537358A Pending JP2014530627A (ja) 2011-10-20 2012-10-22 抗原提示癌ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014537358A Pending JP2014530627A (ja) 2011-10-20 2012-10-22 抗原提示癌ワクチン

Country Status (11)

Country Link
US (2) US20140308316A1 (cg-RX-API-DMAC7.html)
EP (2) EP2768534A4 (cg-RX-API-DMAC7.html)
JP (2) JP2014533938A (cg-RX-API-DMAC7.html)
KR (2) KR20150016200A (cg-RX-API-DMAC7.html)
CN (5) CN105861437A (cg-RX-API-DMAC7.html)
AU (2) AU2012325758A1 (cg-RX-API-DMAC7.html)
CA (2) CA2852960A1 (cg-RX-API-DMAC7.html)
HK (2) HK1201176A1 (cg-RX-API-DMAC7.html)
IL (2) IL232173A0 (cg-RX-API-DMAC7.html)
SG (4) SG11201401632WA (cg-RX-API-DMAC7.html)
WO (2) WO2013059778A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530627A (ja) * 2011-10-20 2014-11-20 カリフォルニア ステム セル インコーポレイテッド 抗原提示癌ワクチン

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
EP3169774A4 (en) * 2014-07-17 2018-04-25 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
WO2017193080A1 (en) * 2016-05-05 2017-11-09 Nantomics, Llc Checkpoint failure and methods therefor
EP3582793A4 (en) * 2017-02-17 2020-12-16 Aivita Biomedical, Inc. METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517946A (ja) * 2004-10-25 2008-05-29 ベイラー・リサーチ・インスチチユート 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
JP2009502955A (ja) * 2005-07-29 2009-01-29 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法
JP2014530627A (ja) * 2011-10-20 2014-11-20 カリフォルニア ステム セル インコーポレイテッド 抗原提示癌ワクチン

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP1056834A2 (en) 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DK1224264T3 (da) 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
RU2313365C2 (ru) * 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
WO2007051316A1 (en) * 2005-11-07 2007-05-10 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
KR20090033375A (ko) * 2006-06-30 2009-04-02 베일러 리서치 인스티튜트 Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517946A (ja) * 2004-10-25 2008-05-29 ベイラー・リサーチ・インスチチユート 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
JP2009502955A (ja) * 2005-07-29 2009-01-29 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法
JP2014530627A (ja) * 2011-10-20 2014-11-20 カリフォルニア ステム セル インコーポレイテッド 抗原提示癌ワクチン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2011, 26(3):345-351, JPN6016036936, ISSN: 0003405927 *
CANCER CELL, 2008, 68(17):6889-6895, JPN6016036935, ISSN: 0003405926 *
INT. J. CANCER, 2008, 122(6):1374-1383, JPN6017032479, ISSN: 0003628712 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530627A (ja) * 2011-10-20 2014-11-20 カリフォルニア ステム セル インコーポレイテッド 抗原提示癌ワクチン
US9555058B2 (en) 2011-10-20 2017-01-31 Neostem Oncology, Llc Antigen presenting cancer vaccine

Also Published As

Publication number Publication date
WO2013059778A2 (en) 2013-04-25
NZ623915A (en) 2016-02-26
EP2768534A4 (en) 2015-04-01
CN105999249A (zh) 2016-10-12
EP2768519A4 (en) 2015-07-01
CN105861437A (zh) 2016-08-17
SG11201401632WA (en) 2014-05-29
SG10201602424RA (en) 2016-05-30
SG11201401631VA (en) 2014-05-29
US20140308316A1 (en) 2014-10-16
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
KR20150004791A (ko) 2015-01-13
CA2852960A1 (en) 2013-04-25
HK1201175A1 (en) 2015-08-28
CN103957925A (zh) 2014-07-30
JP2014530627A (ja) 2014-11-20
NZ623917A (en) 2016-09-30
EP2768534A1 (en) 2014-08-27
IL232173A0 (en) 2014-06-30
AU2012325758A1 (en) 2014-04-24
CA2852967A1 (en) 2013-04-25
US9555058B2 (en) 2017-01-31
EP2768519A2 (en) 2014-08-27
WO2013059778A3 (en) 2013-07-04
WO2013059784A1 (en) 2013-04-25
CN105288602A (zh) 2016-02-03
CN103917246A (zh) 2014-07-09
AU2012325764A1 (en) 2014-04-24
SG10201508535RA (en) 2015-11-27
IL232172A0 (en) 2014-06-30
HK1201176A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
Prue et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A* 0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer
Palucka et al. Recent developments in cancer vaccines
JP2014533938A (ja) γインターフェロンを用いた抗原提示癌ワクチン
Kim et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Montico et al. Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
Duncan et al. A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy
Jenne et al. Dendritic cells pulsed with unfractionated helminthic proteins to generate antiparasitic cytotoxic T lymphocyte
Flores et al. Dendritic Cells Loaded with Heat Shock‐Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell‐Dependent Antitumor Immune Responses In Vitro
US20210403866A1 (en) Enhanced dendritic cell immune activation by combined inhibition of nr2f6 with cannibidiol
Nguyen-Pham et al. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Hüttner et al. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells
Bedrosian et al. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function
Radej et al. Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates
US20170274069A1 (en) Method for the cancer treatment and prevention of metastatic disease
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
Stepanek et al. Effects of 5-azacytidine and trichostatin A on dendritic cell maturation
NZ623917B2 (en) Antigen presenting cancer vaccine
Serine Dendritic Cells Treated with
Ramwarungkura et al. Cordycepin Enhances Dendritic Cell-Mediated T Cell Activation and Anti-Tumor Immunity in Breast Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161226

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170105

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170829